Prevalence of prothrombotic factors in patients with Budd–Chiari syndrome or non‐cirrhotic nonmalignant portal vein thrombosis: A hospital‐based observational study

作者：Jiahao Fan, Qiuhe Wang, Bohan Luo, Hui Chen, Zhengyu Wang, Jing Niu, Jie Yuan, Xulong Yuan, Wei Bai, Chuangye He, Wengang Guo, Kai Li, Zhanxin Yin, Daiming Fan, Guohong Han · 发表于：Journal of Gastroenterology and Hepatology · 年份：2019 · DOI：10.1111/jgh.14925 · 被引用次数：19 · 研究领域：Liver Disease and Transplantation、Myeloproliferative Neoplasms: Diagnosis and Treatment、Venous Thromboembolism Diagnosis and Management

BACKGROUND AND AIM: Comprehensive investigations on the prothrombotic factors of splanchnic vein thrombosis (SVT), including Budd-Chiari syndrome (BCS) and non-cirrhotic nonmalignant portal vein thrombosis (PVT), in Eastern patients are scarce. METHODS: Between March 2012 and July 2017, 812 consecutive patients, including 418 BCS and 394 non-cirrhotic nonmalignant PVT patients, were admitted to Xijing Hospital (a Chinese tertiary academic hospital) and screened for prothrombotic factors. Odds ratios (ORs), 95% confidence intervals (CIs), and P-trends were calculated by using conditional logistic regression. RESULTS: The prevalence of myeloproliferative neoplasms (MPNs) was only 6.3% among BCS patients but 28.3% among PVT patients. Notably, the presence of MPNs was associated with a higher risk of hepatic vein-type BCS (OR 9.9, 95% CI 3.6-26.7, P-trend < 0.001) and extensive thrombosis in PVT (OR 4.1, 95% CI 1.9-8.9, P-trend < 0.001). Calreticulin mutations existed in 2.7% of SVT patients. Furthermore, the prevalence of antiphospholipid antibody syndrome and protein C, protein S, or antithrombin deficiency in BCS patients was 7.3% and 22.5%, respectively, similar to that in patients with PVT (7.4% and 25.7%). In addition, factor V Leiden mutation, prothrombin G20210A mutation, and paroxysmal nocturnal hemoglobinuria were identified in < 1% of both BCS and PVT patients. CONCLUSION: -negative SVT patients in China. However, screening for factor V Leiden mutation, prothrombin G20...